The Charlottesville Angel Network (“CAN”), founded in January 2015, is a growing group of accredited investors who come together on a monthly basis to evaluate start-up company investment presentations in a wide variety of early-stage companies that present high-growth opportunities. CAN’s accredited and qualified investors are high-net worth individuals, family offices, and successful entrepreneurs with profound expertise spanning numerous industries. We couple their financial resources and experience with their dedication to the region’s entrepreneurial ecosystem to drive success for entrepreneurs and their companies.

PorA Pharmaceuticals is developing breakthrough pharmaceuticals to meet the antibiotic challenge. The lead compound is amixicile, a systemic antimicrobial that targets anaerobic organisms through inhibition of pyruvate: ferredoxin oxidoreductase (PFOR). The focus of the company is approval of amixicile to treat Clostridium difficile (c. diff) infection (CDI). CDI has emerged as the most common health-care-associated infection in the USA.

Palvella Therapeutics is a specialty biopharma company centered on relentlessly serving patients through the development and commercialization of novel therapies.

Cavion LLC is a privately held clinical stage platform pharmaceutical company creating therapies engaging the T-type calcium channel (Cav3) for the treatment of neurologic and oncologic diseases. The T-type calcium channel is an emerging molecular target for cancer and pain.Cavion is conducting a multi-site NCI Adult Brain Tumor Consortium-sponsored Phase 1b clinical trial of the T-type calcium channel blocker mibefradil administered with temozolomide in brain cancer and a Yale University-sponsored Phase 1 trial of mibefradil combined with hypofractionated radiation therapy.

The Virginia Distillery Company is bringing the art of crafting authentic Single Malt Whisky to our distillery. Copper pot stills made in Scotland, skilled artisans and a commitment to quality and tradition promise to make ours among the finest whisky available. While the distillery is under construction and our Virginia Single Malt is aging, please enjoy our Virginia Highland Malt whisky.

Ipsen Acquires OctreoPharm Sciences for $55 million in May, 2015. OctreoPharm GmbH is a leading developer of PET molecular diagnostic tracers in Germany. OctreoPharm GmbH’s experienced and motivated management team brings proven track records and decades of experience in the fields of Nuclear Medicine, Oncology, Global Medical Affairs, Drug Development, Regulatory Affairs, Sales & Marketing and Financing to the company and its customers. We are prepared to provide your company with the comprehensive services necessary to launch and sell your radiopharmaceutical, or medical device in Germany or the EU, including extensive contacts with Key Opinion Leaders globally.

Responsible for day-to-day operations of public biopharmaceutical company, including sales, marketing, business development, and legal. Initiated, developed, and implemented all management and financial systems. Managed IPO, a follow-on bond financing and four private financing rounds raising a total of $280MM. In-licensed two clinical stage oncology therapeutics from Novartis and Bayer Schering Pharma. Managed all intellectual property strategy for Company.

Responsible for all day-to-day operations of emerging drug discovery company, including finance, business development, drug development, regulatory, communications and Board activities. Initiated, developed, and implemented all management and financial systems. Repositioned Company from focus on naturally-derived products to drug discovery. Expanded company from research to include a clinical development capability – critical to capturing full value of proprietary compounds. Managed $5MM private financing round. Managed all intellectual property strategy for Company. Responsible for strategic out-licensing agreement with major Chinese pharmaceutical company. Responsible for implementing successful in-licensing agreement. Successfully managed voluntary shutdown of business without bankruptcy.

Initiated, developed and implemented sales and marketing programs for pharmaceutical division including successful launch of Company’s first product Xopenex™ that resulted in first full-year sales of $55MM. Built network of support with medical and patient constituencies resulting in increased market penetration of Xopenex. Developed and implemented policy strategy to optimize reimbursement and patent protection.

Directed the development and implementation of short and long term marketing plans for $200MM plasma products business to achieve divisional sales and profit goals. Identified, analyzed, recommended and implemented new business opportunities and markets globally for plasma products. Created and implemented worldwide health policy strategy and government affairs programs. Achieved 100% price increase through creative management of supply and demand among US and international markets and strategically targeting purchasers to preserve pricing flexibility.

Planned, developed and administered strategic plans for the state government affairs staff. Developed successful programs to protect company products on Medicaid formularies. Responsible for development of strategies that successfully preempted anticipated medical issues and legislation pertaining to the company and the pharmaceutical industry in general. Served as designated company representative to national and state legislative and special interest groups.